Park Place Capital Corp Invests $45,000 in Exelixis, Inc. (NASDAQ:EXEL)

Park Place Capital Corp bought a new position in Exelixis, Inc. (NASDAQ:EXEL) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 2,000 shares of the biotechnology company’s stock, valued at approximately $45,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Raymond James & Associates boosted its holdings in shares of Exelixis by 3.8% during the 4th quarter. Raymond James & Associates now owns 113,631 shares of the biotechnology company’s stock valued at $2,726,000 after acquiring an additional 4,185 shares during the last quarter. New York State Teachers Retirement System raised its position in shares of Exelixis by 2.6% during the fourth quarter. New York State Teachers Retirement System now owns 421,377 shares of the biotechnology company’s stock valued at $10,109,000 after buying an additional 10,617 shares during the last quarter. DekaBank Deutsche Girozentrale raised its position in shares of Exelixis by 55.8% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 380,093 shares of the biotechnology company’s stock valued at $9,065,000 after buying an additional 136,194 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Exelixis by 5.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 34,470 shares of the biotechnology company’s stock worth $827,000 after purchasing an additional 1,853 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its position in Exelixis by 87.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 8,140 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 3,800 shares during the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

EXEL has been the subject of several recent analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $27.00 price objective on shares of Exelixis in a research note on Wednesday, April 10th. StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 13th. Oppenheimer reissued an “outperform” rating and set a $29.00 target price on shares of Exelixis in a research note on Tuesday, July 30th. William Blair reissued an “outperform” rating on shares of Exelixis in a research note on Wednesday, May 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Exelixis in a research note on Friday, May 3rd. Seven equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $26.13.

Exelixis Stock Down 0.2 %

Shares of EXEL traded down $0.05 during midday trading on Friday, reaching $24.17. The company had a trading volume of 1,996,777 shares, compared to its average volume of 1,348,207. Exelixis, Inc. has a 1-year low of $18.64 and a 1-year high of $24.36. The stock has a market cap of $7.33 billion, a PE ratio of 37.77, a price-to-earnings-growth ratio of 0.60 and a beta of 0.54. The firm has a 50 day simple moving average of $22.22 and a 200-day simple moving average of $22.21.

Insider Buying and Selling

In related news, Director Jack L. Wyszomierski sold 8,287 shares of the firm’s stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $22.00, for a total transaction of $182,314.00. Following the completion of the transaction, the director now directly owns 349,499 shares in the company, valued at approximately $7,688,978. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Jack L. Wyszomierski sold 10,923 shares of the firm’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $21.37, for a total transaction of $233,424.51. Following the sale, the director now owns 338,948 shares of the company’s stock, valued at approximately $7,243,318.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jack L. Wyszomierski sold 8,287 shares of the firm’s stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $22.00, for a total value of $182,314.00. Following the sale, the director now directly owns 349,499 shares in the company, valued at approximately $7,688,978. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,896 shares of company stock valued at $660,677. 2.85% of the stock is currently owned by insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.